Effectiveness of low‐dose milnacipran for a patient suffering from pain disorder with delusional disorder (somatic type) in the orofacial region

Glossodynia is chronic pain localized around the tongue, with no perceivable organic abnormalities. In the fields of oral and maxillofacial surgery, it is categorized as an oral psychosomatic disease. In contrast, psychiatric nosology classifies glossodynia as a pain disorder among somatoform disorders, per the DSM‐IV. The patient was a 71‐year‐old woman who developed symptoms of glossodynia, specifically a sore tongue. In the decade before she presented to us, she had had bizarre symptoms of oral cenesthopathy such as the sensation that her teeth had become ‘limp and floppy’ and that she needles in her mouth. Treatment was attempted using several psychotropic drugs, but no satisfactory response was noted. Because the patient was referred to our outpatient clinic, we tried psychotropic therapy again. Additionally, valproic acid, tandospirone and sertraline were administered (in this order), but the patient still showed no response. However, when sertraline was changed to milnacipran, all symptoms disappeared in a short period. We suggest that a small dose of milnacipran can be effective for controlling oral cenesthopathy as well as glossodynia.     

Mini-hyper CVD + CRIB (condensed rituximab,inotuzumab ozogamicin,and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia

Relapsed or refractory pediatric patients with B-acute lymphoblastic leukemia (B-ALL) have high rates of toxicities and relapse, and novel therapy is needed. We present a case of a 5-year-old male child with high-risk B-ALL that was refractory to several re-induction regimens. He was put into minimal residual disease-negative remission after re-induction with chemotherapy plus overlapping rituximab, inotuzumab ozogamicin, and blinatumomab, termed mini-hyper-CVD (cyclophosphamide, vincristine, and dexamethasone) plus CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab). This regimen was well tolerated, and he received his transplant and engrafted with no significant infections, toxicities, or sinusoidal obstruction syndrome. This is the first reported use of a condensed sequential immunotherapy/chemotherapy regimen in a pediatric leukemia patient.     

The role of emotion regulation in mental health during the COVID-19 outbreak: A 10-wave longitudinal study

The COVID-19 pandemic elicited a lot of concerns among citizens, thereby potentially compromising their well-being. This study sought to examine the role of individuals' emotion regulation styles (i.e., emotional dysregulation, emotional suppression, and emotional integration) in handling these concerns and their experiences of well-being (i.e., satisfaction with life and sleep quality) and ill-being (i.e., anxiety and depressive symptoms). The study had a unique 10-wave longitudinal design (N = 986; M_age = 41.28; 76% female) and was conducted during the outbreak of the pandemic in March–May 2020. Multilevel analyses showed, first, that weekly variation in COVID-19 related concerns related negatively to weekly variation in well-being and positively to weekly variation in ill-being. Second, at the between-person level, emotional dysregulation and suppression related positively to between-person vulnerability in ill-being and lower well-being (across all waves). Third, between-person differences in emotional dysregulation amplified the strength of the within-person association between concerns and depressive complaints and lowered life satisfaction. Unexpectedly, integrative emotion regulation amplified the strength of the within-person association between concerns and anxiety. The discussion focuses on the critical role of emotion regulation in handling the uncertainty elicited by the pandemic and provides directions for further research.